Early Bird Special (EBS)

[Bunny]

LIV (baby boomer - biotechs) http://smallcap-sentinel.blogspot.com/2006/03/silver-tsunami-baby-boomers-biotech_15.html Wednesday, March 15, 2006
The Silver Tsunami: Baby Boomers & Biotech Breakthroughs



Originally posted Monday, August 22, 2005 with regular updates below:



It's no secret that expiring patents are an enormous concern for major drug companies like MERCK CO INC (NYSE:MRK) , PFIZER INC (NYSE:PFE), AMGEN (NasdaqNM:AMGN), ASTRAZENECA PLC ADS (NYSE:AZN), Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), Glaxosmithkline PLC (NYSE: GSK), GENENTECH INC (NYSE:DNA), Medimmune Inc. (NasdaqNM: MEDI), Eli Lilly (NYSE: LLY), Neurogen Corporation (NasdaqNM: NRGN), Gene Logic (NasdaqNM:GLGC), Tanox Inc. (NasdaqNM: TNOX) and Novartis AG (NYSE: NVS) especially considering the enormous lawsuits drug companies could face over beleagured drugs once readily sold in the marketplace. Pair the expiration of patents and litigation with an imminent cash cow in the aging baby boomer market soon to be a strong consumer demographic and the timing could be right for emergent biotechnology companies. It may well be the proverbial 'perfect storm.'


Some call this pending horde of Baby Boomers the 81 Million Person Gorilla. During the Baby Boomer years, approximately 76 million American were born. Today, this represents 28 percent of the American population. And they are getting older.

Stents: The Heart of the Matter

As expected, a group of public companies are moving forward in their research and development. Among these technologies are stent makers and perfectors, companies that are intent on innovation regarding stents. Stents are expandable wire-mesh devices placed in clogged blood vessels to prop open the vessels to maintain healthy blood flow to the heart or elsewhere in the body. The major players in the fast-growing multi-billion-dollar worldwide marketplace for implanted, drug-coated vascular stents are Johnson & Johnson Inc. (NYSE:JNJ), Abbott Laboratories (NYSE: ABT), and Boston Scientific Corp. (NYSE:BSX). Click here for FDA definitions on stents.



A recent publication of results of a research study in one of the nation's most respected medical journals, which examined the performance of drug-coated stents in cardiovascular disease patients, recently reported in the Journal of the American Medical Association (JAMA), confirmed findings of prior research indicating that commonly used drug-coated stents cause a much higher rate of complications and death than previously thought. The report further validates the importance of research by stent technology companies toward creation of improved technology, in particular the need for stents that demonstrate improved biocompatibility.



``The results of the study published in JAMA provide important additional data related to this important treatment for cardiovascular disease,'' said SmallCap Sentinel analyst D.R. Clark. ``The study indicates that the most commonly used drug-coated stents cause a higher than expected rate of serious complications in patients who receive them. This further underscores the need for improved stents of precisely the sort being developed by one innovative biomedical company, MIV Therapeutics Inc. (OTCBB:MIVT). The company is using its patented technology to develop an innovative solution to eliminate the complications connected to stents that are outlined in the JAMA article, as well as other studies. The company's proprietary technology uses a unique material called Hydroxyapatite (HAp), which has been shown to have excellent levels of biocompatibility, or friendliness to the human body. Thus, it circumvents serious problems such as inflammation and restenosis, or renarrowing of the arteries, and other complications associated with the drug-coated stents currently on the market. MIVT has developed an ultra-thin, next-generation coating derived from HAp that can coat stents, or other medical devices, to make them bio-friendly. So far, various studies -- including animal trials -- have shown the HAp coatings to have both excellent safety and functionality as a drug-delivery coating. The Company is working towards conducting human clinical trials in its strategy to deliver this new generation of smarter stents to the worldwide marketplace.''

Interested parties may view information about MIVT free of charge via this direct link.

Other stent-related public companies include Angiotech Pharmaceuticals Inc. (NasdaqNM:ANPI), Conor Medsystems Inc. (NasdaqNM:CONR), and Guidant Corp. (NYSE:GDT).

Prominent medical device companies include Baxter International Inc. (NYSE: BAX), Intuitive Surgical Inc (ISRG), ev3, Inc. (NasdaqNM: EVVV), Foxhollow Technologies Inc. (FOXH), Datascope Corp. (NasdaqNM: DSCP), Conceptus Inc. (NasdaqNM: CPTS), Merit Medical Systems Inc. (NasdaqNM: MMSI), FoxHollow Technologies, Inc. (NasdaqNM: FOXH and Arrow International Inc. (NasdaqNM: ARRO).

View Pictures of Stent. Requires "Flash Player" downloadable here.

“Guidant Corporation’s (NYSE:GDT) recent announcement that the company has received Phase II approval from the Food and Drug Administration (FDA) to expand enrollment in the U.S. portion of its SPIRIT III drug eluting stent clinical trial sparked interest in the market,” stated Clark. “Company shares traded enormous volume the day of and following the FDA announcement. Clearly, this indicates great interest in stent related news and success stories.”

Biophan Technologies, Inc. (otcbb: BIPH)

Biophan Technologies, Inc. engages in the development of technologies that enable biomedical devices safe and compatible for use in a magnetic resonance imaging (MRI) machine. Its biomedical devices include implantable medical devices, such as pacemakers, as well as interventional devices, such as minimally invasive surgical tools. Biophan offers MRI shielding for active medical devices; MRI shielding for passive medical devices, including guide wires and biopsy needles; photonic and shielding solutions for MRI imaging; and MRI contrast agents. MRI shielding for passive devices are used in implantable medical devices and in surgery, such as biopsy needles, guide wires, and endoscopes. Photonic and shielding solutions for MRI imaging are used to differentiate between fat, muscle, brain, and other tissue types. MRI contrast agents use either iron oxides or gadolinium-based compounds. The company supplies its technologies primarily to biomedical and biotechnology companies. Biophan was incorporated in 1968 under the name Idaho Copper and Gold, Inc. and changed its name to Idaho Technical, Inc. in 1999. Further, it changed nameto GreatBio Technologies, Inc. in 2000 and to Biophan Technologies, Inc. in 2001. The company is headquartered in West Henrietta, New York.

Additional information regarding Biophan is available at this link.

Callisto Pharmaceuticals (AMEX: KAL)

Callisto is a biopharmaceutical company committed to developing innovative anti-cancer drugs to treat blood cancers and related diseases, including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), relapsed or refractory multiple myeloma, and osteolytic disease. Callisto also has drugs in preclinical development for gastrointestinal inflammation, as well as for protection against the potential bio-warfare agents, staphylococcus and streptococcus.

Callisto's two lead anti-cancer products include Annamycin, a novel liposomal drug from the anthracycline family with potentially reduced cardiotoxicity, a patented liposomal formulation, and the potential to circumvent multi-drug resistance in both ALL and AML; and Atiprimod, a small-molecule oral drug with a potential multiplicity of effects, including tumor cell anti-proliferative and anti-angiogenic activities to treat relapsed multiple myeloma (MM). Atiprimod is presently in a Phase I/IIa clinical trial in relapsed or refractory MM patients at four clinical sites in the U.S. In addition to cancer treatments, Callisto is developing a drug pre-clinically for treatment of inflammatory bowel disease (IBD).

Callisto also has received a major biodefense partnership grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a monoclonal antibody and vaccine against bacterial superantigen toxins. Bacterial superantigens are among the most lethal of toxins that can potentially be used as bioweapons.

A detailed informational report regarding Callisto Pharmaceuticals is available free to the public at the following link:

http://www.trilogy-capital.com/kal_summary.aspx

Dermisonics, Inc. (OTCBB:DMSI)

“The anticipated abundance of aging patients in the coming years is a key factor in the advent of many new technologies within the biotechnology umbrella,” stated SmallCap Sentinel analyst, D.R. Clark. “We’re seeing a concerted effort to develop the ‘better mousetrap’ as companies endeavor to get through development, FDA approvals and eventual product introduction at a commercial level.”

“Unique and improved applications of the transdermal patch, literally and figuratively speaking, are a perfect example,” Clark added. “Dermisonic’s recent announcement that the company has received approval from the Chesapeake Research Review Investigative Review Board to enter into the next stage of human pilot trials of its proprietary U-Strip(TM) Insulin Patch drug-delivery system in patients with Type-2 diabetes affirms the company’s continued success in incubating their core technology.”

Dermisonics, Inc. (OTCBB:DMSI) is a medical device company formed to exploit the vast opportunities for non-invasive, reliable and easy to use delivery of large molecule drugs through its unique, proprietary transdermal patch called the U-Strip.


Interested parties may view information about DMSI free of charge via this direct link: http://www.trilogy-capital.com/dmsi_summary.aspx


The Sagemark Companies, Ltd.,

Sagemark owns, operates and administers out-patient medical diagnostic imaging centers that utilize positron emission tomography (PET), and PET and computed tomography (PET/CT) scanning equipment. PET is an advanced medical diagnostic imaging procedure used by physicians in the detection of certain cancers, coronary disease and neurological disorders including Alzheimer's disease. There are now six PET imaging centers in the company's growing portfolio of medical diagnostic imaging facilities.

The Sagemark Companies, Ltd., through its wholly-owned subsidiary, Premier P.E.T. Imaging International, Inc., engages in the acquisition, operation, and management of outpatient medical diagnostic imaging centers. Its diagnostic imaging centers utilize positron emission tomography (PET) scanning equipment that perform PET scans on patients for the purpose of detecting cancer. As of June 30, 2005, the company owned and/or operated five PET imaging centers in Kansas, New York, New Jersey, and Florida. The Sagemark Companies was founded in 1961 and is based in New York City.

Samaritan Pharmaceuticals Inc. (AMEX: LIV)

Samaritan is a drug development company driven to discover, develop and commercialize new, innovative drugs for AIDS, Alzheimer’s, Cancer and Heart disease. Samaritan is currently advancing eight promising compounds out of its rich pipeline of 250 possible drug candidates, all of which have the potential to create revenue-generating opportunities. In addition, the majority of Samaritan’s patented drugs are credentialed with peer-reviewed journals and some with National Institutes of Health (NIH) grants. .

A detailed informational report regarding Samaritan is available free to the public at the following link:

http://stockupticks.com/profiles/3-15-06.html

Disclaimer: Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect the results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project its capabilities, intent, resources, or experience.

The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. MP has been paid $1500 by McCloud Communications for this report and other advertising services. MP is not an investment advisor and this report is not investment advice. MP has not been paid for preparation and distribution of this report but MP has been paid $1,500 each BY MIVT, DMSI, AND by BIPH for preparation and distribution of other current reports (per report) and other advertising services over the next 30 days. MP has been paid fifteen hundred dollars by Callisto for this report and other advertising services. Additionally, MP and/or its affiliates, associates and employees from time to time may have either a long or short position in any securities mentioned. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject companies.

D.R. Clark, Kurt Divich & Shannon Squyres have contributed to this informational report in various passages.

posted by StockUpTicks.com at 7:00 PM

0 Comments:
Post a Comment

<< Home
Previous Posts
The Evils of EBITDA
REPORT: Looking at Real Estate from a Stock Market Angle.
ANALYST NOTES: Technology Growth, Emerging Companies & Emerging Markets
REPORT: Looking at the Political Impact on Stem Cell Research
Investing in Metal Related Stocks for the SmallCap Investor
Analyst: Nanotechnology Outlook
Batter Up! Analysis of the Energy Market
Homeland Defense & The Market.